Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GALECTIN THERAPEUTICS INC.

(GALT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Galectin Therapeutics Inc. Announces Board Appointments

08/30/2021 | 08:00am EDT

Galectin Therapeutics Inc. announced that the company has recently expanded its management team with multiple key leadership appointments, including Dakshina Reddy, MSM, as Executive Director, Regulatory Affairs; Ezra R. Lowe, Ph.D., as Executive Director, Clinical and Preclinical Pharmacology; Marla Mills-Wilson as Executive Director, Clinical Operations; and Jessica Kopaczewski as Associate Director, Clinical Operations. These strategic appointments strengthen the company’s clinical, regulatory, and operational efforts across its ongoing programs in cancer immunotherapy and NASH cirrhosis. Dakshina Reddy most recently worked for Novartis as Global Program Regulatory Director, where he led and achieved successful approvals of IND’s, NDA’s, sNDA’s and MAA’s in the U.S., E.U., Japan, China, Brazil and Mexico. Ezra R. Lowe, Ph.D. Prior to joining Galectin, Ezra was Senior Director, Clinical Pharmacology in Global R&D with the Bausch Health Companies.


© S&P Capital IQ 2021
All news about GALECTIN THERAPEUTICS INC.
10/06GALECTIN THERAPEUTICS : to Participate in the H.C. Wainwright 5th Annual NASH Investor Con..
AQ
10/05UPDATE : Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Inves..
GL
10/05UPDATE : Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Inves..
GL
10/05GALECTIN THERAPEUTICS : to Participate in the H.C. Wainwright 23rd Annual Global Investmen..
AQ
09/21GALECTIN THERAPEUTICS : Secures $20 Million Debt Financing from Chairman Richard Uihlein
MT
09/21GALECTIN THERAPEUTICS : Announces $20 Million Convertible Debt Financing from Its Chairman..
PU
09/21GALECTIN THERAPEUTICS : Announces $20 Million Convertible Debt Financing from Its Chairman..
AQ
09/21GALECTIN THERAPEUTICS INC : Entry into a Material Definitive Agreement, Creation of a Dire..
AQ
09/17Galectin Therapeutics Inc. announced that it expects to receive $20 million in funding
CI
09/13GALECTIN THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
More news
Analyst Recommendations on GALECTIN THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -36,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,37x
Yield 2021 -
Capitalization 191 M 191 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 6
Free-Float 70,5%
Chart GALECTIN THERAPEUTICS INC.
Duration : Period :
Galectin Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALECTIN THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 3,22 $
Average target price 14,00 $
Spread / Average Target 335%
EPS Revisions
Managers and Directors
Joel Lewis President, Chief Executive Officer & Director
Jack W. Callicutt Chief Financial Officer & Secretary
Richard E. Uihlein Chairman
Pol F. Boudes Chief Medical Officer
Ezra R. lowe Executive Director-Clinical
Sector and Competitors
1st jan.Capi. (M$)
GALECTIN THERAPEUTICS INC.46.88%195
MODERNA, INC.225.04%134 418
LONZA GROUP AG29.18%59 339
IQVIA HOLDINGS INC.42.23%48 194
SEAGEN INC.-0.71%31 811
CELLTRION, INC.-39.42%25 446